|
| General Information |
| Business: |
We are a clinical-stage therapeutics company focused on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. We have two programs in advanced clinical development. The first program, INOpulse, is based on our proprietary pulsatile nitric oxide delivery device. We are currently developing two product candidates under our INOpulse program: one for the treatment of pulmonary arterial hypertension, or PAH, for which we intend to commence Phase 3 clinical trials in the second half of 2015, and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH-COPD, which is in Phase 2 development. Our second program is bioabsorbable cardiac matrix, or BCM, which is currently in a placebo-controlled clinical trial designed to support CE mark registration in the European Union. We completed enrollment of this trial in December 2014, with 303 patients having completed the treatment procedure, and we expect to report top line results in mid-2015. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
48 |
Founded: |
2013 |
|
| Contact Information |
| Address: |
53 Frontage Road, Suite 301, Hampton, New Jersey 08827, US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -63.7 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
BLPH |
| Shares (millions): |
5.0 |
| Price Range: |
$12.00 - $12.00 |
| Est.$ Volume |
$ 60.0 mil |
| Manager / Joint Managers |
Leerink Partners/ Cowen and Company |
| Co Managers |
FBR/ SunTrust Robinson Humphrey |
| Expected to Trade |
2/13/2015 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
